NEW YORK (TheStreet) -- Shares of Shire Plc (SHPG - Get Report) are up 1.81% to $175.45 in pre-market trade after Allergan Inc. (AGN - Get Report) will reportedly approach Shire again about a potential takeover after being rebuffed in recent months, sources told Reuters.
A bid by Allergan for Shire, which has a market value of $32 billion, would underscore how keen the U.S. dermatology drugmaker is to stay independent, Reuters reports.
- The revenue growth came in higher than the industry average of 1.4%. Since the same quarter one year prior, revenues slightly increased by 9.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
- SHPG has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, SHPG has a quick ratio of 1.89, which demonstrates the ability of the company to cover short-term liquidity needs.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Pharmaceuticals industry and the overall market, SHIRE PLC's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- Powered by its strong earnings growth of 1172.72% and other important driving factors, this stock has surged by 80.76% over the past year, outperforming the rise in the S&P 500 Index during the same period. Turning to the future, naturally, any stock can fall in a major bear market. However, in almost any other environment, the stock should continue to move higher despite the fact that it has already enjoyed nice gains in the past year.
- SHIRE PLC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, SHIRE PLC increased its bottom line by earning $7.36 versus $3.89 in the prior year. This year, the market expects an improvement in earnings ($9.48 versus $7.36).
- You can view the full analysis from the report here: SHPG Ratings Report